Rapid, Serial, Non-invasive Assessment of Drug Efficacy in Mice with Autoluminescent Mycobacterium ulcerans Infection

PLoS Neglected Tropical Diseases

Volumn 7, Issue 12, 2013, Pages

  Zhang, Tianyu ^a,b   Li, Si Yang ^a   Converse, Paul J ^a   Grosset, Jacques H ^a   Nuermberger, Eric L ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CLARITHROMYCIN; HYGROMYCIN; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL VIRULENCE; BIOLUMINESCENCE; BURULI ULCER; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; FOOT PAD; GROWTH CURVE; MOUSE; NONHUMAN;

ANIMALS; BURULI ULCER; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; LOWER EXTREMITY; LUMINESCENT MEASUREMENTS; MICE; MICE, INBRED BALB C; MYCOBACTERIUM ULCERANS; STAINING AND LABELING; TIME FACTORS;

EID: 84892728268     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002598     Document Type: Article

References (32)

1. Portaels F, Silva MT, Meyers WM, (2009) Buruli ulcer. Clin Dermatol 27: 291-305.
2. van der Werf TS, Stienstra Y, Johnson RC, Phillips R, Adjei O, et al. (2005) Mycobacterium ulcerans disease. Bull World Health Organ 83: 785-791.
3. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854-857.
4. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, et al. (2004) Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A 101: 1345-1349.
5. Converse PJ, Almeida DV, Nuermberger EL, Grosset JH, (2011) BCG-Mediated Protection against Mycobacterium ulcerans Infection in the Mouse. PLoS Neglected Tropical Diseases 5: e985.
6. Dega H, Robert J, Bonnafous P, Jarlier V, Grosset J, (2000) Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 44: 2367-2372.
7. Lefrancois S, Robert J, Chauffour A, Ji B, Jarlier V, (2007) Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin. Antimicrob Agents Chemother 51: 645-650.
8. Chauty A, Ardant M-F, Adeye A, Euverte H, Guedenon A, et al. (2007) Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli Ulcer (Mycobacterium ulcerans Disease). Antimicrob Agents Chemother 51: 4029-4035.
9. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, et al. (2005) Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans. Antimicrob Agents Chemother 49: 3182-3186.
10. Kibadi K, Boelaert M, Fraga AG, Kayinua M, Longatto-Filho A, et al. (2010) Response to Treatment in a Prospective Cohort of Patients with Large Ulcerated Lesions Suspected to Be Buruli Ulcer (Mycobacterium ulcerans Disease). PLoS Negl Trop Dis 4: e736.
11. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, et al. (2010) Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. The Lancet 375: 664-672.
12. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, et al. (2010) Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 54: 3678-3685.
13. World Health Organization (2007) Global plan to combat neglected tropical diseases, 2008-2015. World Health Organization.
14. Converse PJ, Xing Y, Kim KH, Tyagi S, Li SY, et al. (2013) Fluorescent thin layer chromatography revisited: Absolute ethanol preserves mycolactone in mouse tissue. Geneva, Switzerland. pp. 43-44.
15. Sarfo FS, Converse PJ, Almeida DV, Zhang J, Robinson C, et al. (2013) Microbiological, Histological, Immunological, and Toxin Response to Antibiotic Treatment in the Mouse Model of Mycobacterium ulcerans Disease. PLoS Negl Trop Dis 7: e2101.
16. Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, et al. (2011) Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice. PLoS Negl Trop Dis 5: e933.
17. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, et al. (2010) Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One 5: e10777.
18. Heuts F, Carow B, Wigzell H, Rottenberg ME, (2009) Use of non-invasive bioluminescent imaging to assess mycobacterial dissemination in mice, treatment with bactericidal drugs and protective immunity. Microbes Infect 11: 1114-1121.
19. Hickey MJ, Arain TM, Shawar RM, Humble DJ, Langhorne MH, et al. (1996) Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob Agents Chemother 40: 400-407.
20. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966.
21. Zhang T, Bishai WR, Grosset JH, Nuermberger EL, (2010) Rapid Assessment of Antibacterial Activity against Mycobacterium ulcerans by Using Recombinant Luminescent Strains. Antimicrob Agents Chemother 54: 2806-2813.
22. Zhang T, Li S-Y, Converse PJ, Almeida DV, Grosset JH, et al. (2011) Using Bioluminescence To Monitor Treatment Response in Real Time in Mice with Mycobacterium ulcerans Infection. Antimicrob Agents Chemother 55: 56-61.
23. Hakkila K, Maksimow M, Karp M, Virta M, (2002) Reporter genes lucFF, luxCDABE, gfp, and dsred have different characteristics in whole-cell bacterial sensors. Anal Biochem 301: 235-242.
24. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, et al. (1991) New use of BCG for recombinant vaccines. Nature 351: 456-460.
25. Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL, (2011) Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 184: 732-737.
26. Winson MK, Swift S, Hill PJ, Sims CM, Griesmayr G, et al. (1998) Engineering the luxCDABE genes from Photorhabdus luminescens to provide a bioluminescent reporter for constitutive and promoter probe plasmids and mini-Tn5 constructs. FEMS Microbiol Lett 163: 193-202.
27. Zhang T, Li S-Y, Nuermberger EL, (2012) Autoluminescent Mycobacterium tuberculosis for Rapid, Real-Time, Non-Invasive Assessment of Drug and Vaccine Efficacy. PLoS ONE 7: e29774.
28. Williamson HR, Benbow ME, Nguyen KD, Beachboard DC, Kimbirauskas RK, et al. (2008) Distribution of Mycobacterium ulcerans in Buruli Ulcer endemic and non-endemic aquatic sites in Ghana. PLoS Neglected Tropical Diseases 2: e205.
29. Craig WA, Ebert SC, (1990) Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl 74: 63-70.
30. Ji B, Lefrancois S, Robert J, Chauffour A, Truffot C, et al. (2006) In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 50: 1921-1926.
31. Portaels F, Traore H, De Ridder K, Meyers WM, (1998) In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob Agents Chemother 42: 2070-2073.
32. Thangaraj HS, Adjei O, Allen BW, Portaels F, Evans MR, et al. (2000) In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J Antimicrob Chemother 45: 231-233.